Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy

Phase 3

• Conditions: Safety and Feasibility of Dexmedetomidine Sedation for Awake Fibreoptic Bronchoscopy; Anaesthesiology - Anaesthetics

• Registration Number: ACTRN12608000304336
• Lead Sponsor: Keat Lee

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-06-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

18 years and above, Presenting for awake fibreoptic bronchoscopy, and
Not pregnant at the start of the procedure/sedation

Exclusion Criteria

Allergy to dexmedetomidine,2nd degree heart block and above,Hypovolaemia,Hypotensive at the start of the procedure/sedation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemodynamic changes from baseline<br>(observational), Heart rate, Non-invasive blood pressure - systolic, mean and diastolic blood pressure[Baseline, during the sedation and 30 minutes after sedation ceasing (or return to baseline hemodynamics)]

Secondary Outcome Measures

Name	Time	Method
Ramsay Sedation Score[Baseline, during the sedation and 30 mins after ceasing sedation];Adverse events monitoring<br>Bradycardia (Heart rate (HR) <40), Hypotension (Mean Arterial Pressure (MAP)<55mmHg), Nausea[During the sedation and 30 mins after ceasing sedation];Patient Satisfaction (interview, visual analogue scale)[1 hour post procedure];Proceduralist Satisfaction (visual analogue scale)[Immediately after the procedure]